vs
Side-by-side financial comparison of Arlo Technologies, Inc. (ARLO) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
Arlo Technologies, Inc. is the larger business by last-quarter revenue ($141.3M vs $86.8M, roughly 1.6× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 16.2%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 6.7%).
Arlo Technologies is an American company that makes wireless surveillance cameras. Prior to an initial public offering (IPO) on the New York Stock Exchange in August 2018, Arlo was a brand of such products by Netgear, which retained majority control after the IPO.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
ARLO vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $141.3M | $86.8M |
| Net Profit | $5.8M | — |
| Gross Margin | 46.4% | 67.4% |
| Operating Margin | 3.3% | -84.7% |
| Net Margin | 4.1% | — |
| Revenue YoY | 16.2% | 17.7% |
| Net Profit YoY | 218.6% | — |
| EPS (diluted) | $0.06 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $141.3M | $86.8M | ||
| Q3 25 | $139.5M | $67.5M | ||
| Q2 25 | $129.4M | $60.0M | ||
| Q1 25 | $119.1M | $49.3M | ||
| Q4 24 | $121.6M | $73.7M | ||
| Q3 24 | $137.7M | $58.6M | ||
| Q2 24 | $127.4M | $31.1M | ||
| Q1 24 | $124.2M | $715.0K |
| Q4 25 | $5.8M | — | ||
| Q3 25 | $6.9M | $-91.3M | ||
| Q2 25 | $3.1M | $-111.7M | ||
| Q1 25 | $-835.0K | $-116.2M | ||
| Q4 24 | $-4.9M | — | ||
| Q3 24 | $-4.4M | $-83.5M | ||
| Q2 24 | $-11.6M | $-97.1M | ||
| Q1 24 | $-9.6M | $-113.0M |
| Q4 25 | 46.4% | 67.4% | ||
| Q3 25 | 40.5% | 43.0% | ||
| Q2 25 | 44.9% | 5.5% | ||
| Q1 25 | 44.3% | -0.8% | ||
| Q4 24 | 36.9% | 68.7% | ||
| Q3 24 | 35.2% | 46.2% | ||
| Q2 24 | 36.8% | -0.8% | ||
| Q1 24 | 38.1% | — |
| Q4 25 | 3.3% | -84.7% | ||
| Q3 25 | 0.6% | -140.7% | ||
| Q2 25 | 1.5% | -189.8% | ||
| Q1 25 | -1.2% | -245.8% | ||
| Q4 24 | -5.0% | -117.5% | ||
| Q3 24 | -4.0% | -152.1% | ||
| Q2 24 | -10.0% | -327.6% | ||
| Q1 24 | -8.5% | -16464.6% |
| Q4 25 | 4.1% | — | ||
| Q3 25 | 4.9% | -135.3% | ||
| Q2 25 | 2.4% | -186.2% | ||
| Q1 25 | -0.7% | -235.5% | ||
| Q4 24 | -4.0% | — | ||
| Q3 24 | -3.2% | -142.7% | ||
| Q2 24 | -9.1% | -312.2% | ||
| Q1 24 | -7.8% | -15800.8% |
| Q4 25 | $0.06 | — | ||
| Q3 25 | $0.06 | — | ||
| Q2 25 | $0.03 | $-0.33 | ||
| Q1 25 | $-0.01 | $-0.36 | ||
| Q4 24 | $-0.05 | $-0.24 | ||
| Q3 24 | $-0.04 | $-0.28 | ||
| Q2 24 | $-0.12 | $-0.34 | ||
| Q1 24 | $-0.10 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $146.4M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $127.8M | $698.6M |
| Total Assets | $310.5M | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $146.4M | $297.0M | ||
| Q3 25 | $86.0M | $300.8M | ||
| Q2 25 | $71.2M | $301.2M | ||
| Q1 25 | $84.0M | $359.7M | ||
| Q4 24 | $82.0M | $323.8M | ||
| Q3 24 | $77.0M | $397.5M | ||
| Q2 24 | $62.9M | $412.5M | ||
| Q1 24 | $62.1M | $356.2M |
| Q4 25 | $127.8M | $698.6M | ||
| Q3 25 | $129.2M | $702.3M | ||
| Q2 25 | $118.3M | $698.5M | ||
| Q1 25 | $103.4M | $767.9M | ||
| Q4 24 | $100.9M | $710.4M | ||
| Q3 24 | $96.9M | $773.5M | ||
| Q2 24 | $99.3M | $768.5M | ||
| Q1 24 | $99.9M | $680.0M |
| Q4 25 | $310.5M | $913.2M | ||
| Q3 25 | $350.9M | $904.9M | ||
| Q2 25 | $319.7M | $907.4M | ||
| Q1 25 | $296.6M | $966.7M | ||
| Q4 24 | $298.4M | $910.4M | ||
| Q3 24 | $312.4M | $991.1M | ||
| Q2 24 | $295.8M | $964.3M | ||
| Q1 24 | $289.8M | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $19.8M | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | 3.43× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.8M | $-52.6M | ||
| Q3 25 | $19.2M | $-78.7M | ||
| Q2 25 | $8.8M | $-67.4M | ||
| Q1 25 | $30.9M | $-103.7M | ||
| Q4 24 | $6.7M | $-73.3M | ||
| Q3 24 | $18.4M | $-59.0M | ||
| Q2 24 | $6.5M | $-98.4M | ||
| Q1 24 | $19.8M | $-122.3M |
| Q4 25 | — | $-61.9M | ||
| Q3 25 | — | $-89.5M | ||
| Q2 25 | — | $-74.9M | ||
| Q1 25 | $28.1M | $-109.9M | ||
| Q4 24 | $5.6M | $-77.5M | ||
| Q3 24 | $17.4M | $-61.3M | ||
| Q2 24 | $6.2M | $-98.9M | ||
| Q1 24 | $19.4M | $-126.5M |
| Q4 25 | — | -71.3% | ||
| Q3 25 | — | -132.7% | ||
| Q2 25 | — | -124.9% | ||
| Q1 25 | 23.6% | -222.8% | ||
| Q4 24 | 4.6% | -105.1% | ||
| Q3 24 | 12.6% | -104.6% | ||
| Q2 24 | 4.8% | -317.9% | ||
| Q1 24 | 15.7% | -17685.3% |
| Q4 25 | — | 10.7% | ||
| Q3 25 | — | 16.1% | ||
| Q2 25 | — | 12.4% | ||
| Q1 25 | 2.4% | 12.6% | ||
| Q4 24 | 0.9% | 5.7% | ||
| Q3 24 | 0.7% | 3.9% | ||
| Q2 24 | 0.2% | 1.4% | ||
| Q1 24 | 0.3% | 583.4% |
| Q4 25 | 3.43× | — | ||
| Q3 25 | 2.79× | — | ||
| Q2 25 | 2.83× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ARLO
| Subscriptions And Services | $89.4M | 63% |
| Products | $51.9M | 37% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
